Regeneron Pharmaceuticals, gene therapy and deafness

Regeneron (REGN) announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have ...
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
On February 18, 2025, in a closely watched decision, the United States Court of Appeals for the First Circuit in United States v.
Regeneron is also embroiled in a securities fraud class action lawsuit stemming from a significant stock price drop on October 31, 2024. Shares plunged $84.59 that day, wiping out approximately $9 ...
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
Key Takeaways - The First Circuit ruled in United States v. Regeneron Pharmaceuticals, Inc., that the government must prove but-for causation ...